An observational study in Respiratory Infection (for Example, Pneumonia, Bronchitis), Antibiotic and Antibiotic Duration, sponsored by Intermountain Health Care, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Intermountain Health Care, Inc. · Observational
The goal of this implementation project is to detail the process of implementing the best practice of antibiotic stewardship in the pediatric population across the Intermountain Health medical system. The main questions it aims to answer are:
Data will be collected on number of children reached, adherence changes over time, types of implementation strategies employed, and characteristics of sites, prescribers, and patients.
751 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.
This study's planned enrollment of 259,000 is above the median of 350 across 184 observational studies indexed under Respiratory Tract Infections.
Browse Respiratory Tract Infections studies →Intermountain Health Care, Inc. is the lead sponsor of 120 studies on the registry; 15 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 3 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
All children meeting eligibility criteria and treated at any facility within the Intermountain region specified (wave 1 \& wave 2) between January 1, 2026 and December 31, 2028.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children under 18 treated in Wave 1 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP)
Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation
Children under 18 treated in Wave 2 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP)
Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation
o facilitate improved adherence to guideline-based prescribing, we plan a variety of implementation strategies to be employed in tandem including training \& education, EMR tools (e.g., Smart sets, express lanes, preference lists), audit and feedback reports and dashboards, and facilitation.
Guideline-adherent Broad vs. Narrow Spectrum Antibiotic Prescribing
Rates of narrow-spectrum antibiotic (AB) prescriptions as a proportion of all antibiotics prescribed in aggregate and within each of these diagnoses: Acute otitis media, Group A streptococcal pharyngitis, Acute sinusitis, and Pneumonia.
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Guideline-adherent Duration of Antimicrobial Therapy
Rate of AB prescriptions with guideline-adherent number of days prescribed as proportion of all AB prescriptions in aggregate and for each of the target ARTI diagnoses.
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Rate of Treatment Failure
Clinical encounter for the same diagnosis between 2 and 14 days following the index encounter and receipt of an alternative antibiotic for the same respiratory diagnosis during the return visit.
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Staff): Adherence to Protocols
Number and proportion of prescribers who are "adherent" to guideline-based prescribing protocols for Broad vs. Narrow Spectrum AB Prescribing, and Duration.
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Organization): Adherence to Protocols
Number and proportion of sites where 60% of prescribers are adherent.
Time frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Plan to share: No — This is an implementation study using observational data with a waiver of consent. Therefore, there is no consent to allow for the sharing of IPD.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2029, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →
Intermountain Health Care, Inc. →